Company Overview

NeuroSense Therapeutics Ltd. is a clinical-stage biotechnology company focused on the development of novel disease-modifying therapies for neurodegenerative diseases, with a primary emphasis on amyotrophic lateral sclerosis (ALS). The company operates within the biopharmaceutical and neuroscience therapeutics industries and is publicly traded on the Nasdaq Capital Market under the ticker NRSN. Its core mission is to address conditions with significant unmet medical needs through combination therapies that target multiple disease mechanisms simultaneously.

The company’s lead product candidate, PrimeC, is designed as a proprietary extended-release oral formulation combining two existing FDA-approved drugs intended to modulate complementary pathological pathways associated with ALS, including neuroinflammation and neurodegeneration. NeuroSense was founded in Israel and has evolved from preclinical research into a late clinical-stage company, advancing PrimeC through multi-country clinical trials while positioning itself for potential regulatory engagement in major pharmaceutical markets.

Business Operations

NeuroSense’s operations are primarily centered on research and development, clinical trial execution, regulatory strategy, and intellectual property management. The company currently operates as a single-reportable segment focused on the development of PrimeC, which represents its principal asset and primary driver of corporate value. Revenue generation is not yet material, as the company remains in the clinical development stage and does not market approved products.

Operational activities include the management of Phase II clinical studies, engagement with contract research organizations, manufacturing of clinical trial materials, and collaboration with academic and clinical research centers. The company conducts operations across Israel, the United States, and Europe, relying on external partners for clinical trial sites and specialized development services. Data on formal subsidiaries, joint ventures, or revenue-generating commercial partnerships is inconclusive based on available public sources.

Strategic Position & Investments

Strategically, NeuroSense is focused on advancing PrimeC toward late-stage clinical development and potential regulatory approval for ALS. The company’s approach emphasizes drug repurposing combined with proprietary formulation technology, which management believes may reduce development risk and timelines compared to entirely novel compounds. Growth initiatives are largely centered on clinical milestone achievement, regulatory pathway clarification, and potential strategic partnerships with larger pharmaceutical companies.

NeuroSense has not disclosed completed acquisitions of other companies or ownership of diversified portfolio assets. Investment activity is primarily directed toward internal R&D, clinical trials, and intellectual property protection related to PrimeC. The company has also indicated interest in expanding its platform to address additional neurodegenerative indications, although specific programs beyond ALS are not conclusively detailed in public filings.

Geographic Footprint

NeuroSense is headquartered in Israel, where its core research leadership and corporate management are based. The company maintains an operational presence in North America and Europe through clinical trial activities, regulatory interactions, and investor relations, reflecting its focus on major pharmaceutical markets and ALS patient populations.

Clinical studies for PrimeC have been conducted across multiple countries, including sites in the United States and Europe, supporting the company’s strategy to pursue global regulatory approval. While the company does not operate large-scale physical facilities internationally, its development activities demonstrate a growing international footprint aligned with global clinical development standards.

Leadership & Governance

NeuroSense was co-founded by individuals with experience in biotechnology, drug development, and life sciences entrepreneurship. The leadership team emphasizes a strategy centered on scientific rigor, efficient clinical execution, and addressing unmet needs in neurodegenerative diseases. Governance is overseen by a board of directors consistent with U.S. public company requirements following its Nasdaq listing.

Key executives include:

• Alon Ben-Noon – Chief Executive Officer
• Nir Levi – Chief Financial Officer
• Dr. Tamar Ben‑Harosh – Vice President, Research and Development
• Irit Akirav – Vice President, Clinical Operations

The leadership philosophy emphasizes translational science and disciplined capital allocation to advance PrimeC while maintaining regulatory and clinical credibility. Titles and executive roles are based on publicly available disclosures; however, some role definitions may vary slightly across reporting periods based on company filings.